What was recalled
This page synthesizes the source-form and metabolism framework around vitamin B6 in commercial pet food. Vitamin B6 is the cofactor pool for one of the most metabolically diverse enzyme families in mammalian biochemistry, with over 140 catalogued pyridoxal-5-phosphate-dependent reactions. The most quantitatively important destinations include amino acid transamination (PLP is the cofactor for essentially every aminotransferase, transferring amino groups between alpha-amino acids and alpha-keto acids), amino acid decarboxylation (producing neurotransmitters including serotonin from 5-hydroxytryptophan, dopamine from L-DOPA, GABA from glutamate, histamine from histidine), glycogen phosphorylase (the rate-limiting enzyme of glycogen mobilization to glucose-1-phosphate), heme biosynthesis through delta-aminolevulinate synthase, cystathionine beta-synthase in homocysteine catabolism to cystathionine and ultimately cysteine, and kynurenine pathway tryptophan catabolism reactions. Dietary B6 deficiency manifests across multiple physiologic systems — microcytic hypochromic anemia (impaired heme biosynthesis), peripheral neuropathy (impaired neurotransmitter synthesis), dermatitis (mechanism less well-defined), and in severe cases seizures and growth retardation.
The natural vitamin B6 forms have specific tissue distribution patterns. Pyridoxine (PN) and its 5-phosphate (PNP) predominate in plant tissue, with the glycoside conjugate pyridoxine-5’-beta-D-glucoside (PNG) being a poorly bioavailable form found in some plant matrices. Pyridoxal (PL) and pyridoxal-5-phosphate (PLP) predominate in animal tissue, where they exist bound to enzyme apoproteins. Pyridoxamine (PM) and pyridoxamine-5-phosphate (PMP) also occur in animal tissue at lower concentration. Intestinal absorption proceeds through dephosphorylation of phosphate esters by intestinal alkaline phosphatase, transport of free PN / PL / PM across enterocyte membranes, hepatic uptake, and conversion to PLP through pyridoxal kinase (PL or PN to PLP) and pyridoxine 5-phosphate oxidase (the riboflavin-dependent enzyme that oxidizes PNP and PMP to PLP). The riboflavin dependency of the oxidase step is the structural foundation for the B6 / riboflavin / folate cross-cofactor adequacy framework in commercial pet food formulation.
Commercial pet food vitamin B6 supplementation uses pyridoxine hydrochloride (PN-HCl) almost universally for cost and shelf stability. The compound is white crystalline solid, highly water-soluble, and stable across the temperature and moisture range of standard pet food manufacturing. Extrusion processing destroys approximately 10-20% of supplemented pyridoxine HCl through Maillard reaction and oxidative degradation; retort canning destroys more. Natural vitamin B6 contribution from animal-tissue ingredients can be substantial — liver delivers 5-15 mg/kg fresh weight, muscle meat 1-3 mg/kg, and tuna and salmon are particularly rich at 5-10 mg/kg. The natural contribution provides predominantly PL and PLP rather than PN, which is theoretically more efficiently converted to active PLP because it bypasses the riboflavin-dependent oxidase step that PN-HCl supplementation must traverse. Direct PLP supplementation appears in some specialty human supplements and is essentially absent from commercial pet food.
Why it was recalled
The structural controversy has three layers. Layer one — PN-HCl conversion requires adequate riboflavin status: the pyridoxine 5-phosphate oxidase enzyme that converts PNP and PMP to active PLP is riboflavin-dependent. Pets with marginal riboflavin status (uncommon at AAFCO compliance but possible in chronic enteropathies or boutique formulations) can have impaired functional B6 status despite adequate dietary pyridoxine intake because the oxidase step is rate-limited by riboflavin availability. The interaction is documented in mammalian biochemistry literature and applies in principle to companion-animal nutrition. Animal-tissue-derived PL and PLP bypass the riboflavin-dependent step and deliver more direct functional B6, which is one structural reason named-meat-anchored formulations may deliver more robust functional B6 than equivalent supplemented-with-PN-HCl plant-protein formulations.
Layer two — carnivore amino-acid-catabolism load drives feline requirement: AAFCO sets feline pyridoxine minimum at 4 mg/kg dry matter and canine minimum at 1.5 mg/kg — approximately 2.7x feline-to-canine ratio. The higher feline requirement reflects obligate-carnivore physiology and the high gluconeogenic flux through hepatic and renal transamination reactions. Cats have constitutively elevated hepatic aminotransferase activity compared to dogs, which translates into higher PLP cofactor turnover and higher dietary pyridoxine requirement at equivalent body weight. Plant-protein-heavy feline formulations face the dual challenge of providing high-quality protein with adequate sulfur amino acid content (covered on our methionine source and synthetic taurine controversy pages) and adequate pyridoxine availability to support the transamination load.
Layer three — PNG plant glycoside bioavailability gap: pyridoxine-5’-beta-D-glucoside (PNG) is a poorly bioavailable B6 form found in some plant matrices, particularly in legumes, rice bran, and certain whole grains. Total B6 measurement by standard analytical methods can include the PNG fraction without distinguishing its reduced bioavailability. Pet food formulations with high inclusion of plant-protein concentrates may report total B6 content on guaranteed analysis that includes PNG-contributed B6 not fully bioavailable in vivo. The interaction is well-documented in human nutrition literature and applies in principle to companion-animal formulation. Brands using meat-anchored protein bases plus pyridoxine HCl supplementation deliver more robustly bioavailable B6 than plant-protein-heavy formulations that rely on PNG-contributing plant matrices to contribute to the AAFCO minimum.
Health risks for your pet
Clinical vitamin B6 deficiency in commercial-fed dogs and cats is uncommon at the population level because of AAFCO-mandated supplementation. Disproportionate deficiency risk concentrates in pets on isoniazid therapy (the antitubercular drug is a B6 antagonist used uncommonly in veterinary medicine), pets on prolonged sulfonamide antibiotic therapy in some cases, pets with chronic enteropathies and concurrent multi-B-vitamin malabsorption, and boutique-formulation and homemade-diet feeders without certified nutritionist oversight. Clinical signs include microcytic hypochromic anemia (impaired heme biosynthesis), peripheral neuropathy and ataxia (impaired neurotransmitter synthesis), seborrheic dermatitis, oxalate crystalluria (glyoxylate transamination requires PLP), and in severe cases seizures. Diagnosis is typically presumptive based on diet history and clinical response to supplementation rather than direct serum measurement, since serum PLP is not a routine veterinary assay.
Vitamin B6 excess from dietary sources alone is uncommon but documented from inappropriate pharmacologic-dose supplementation. Chronic high-dose pyridoxine (typically over 50-100 mg/kg body weight per day for weeks to months) can produce sensory neuropathy in dogs — the same syndrome documented in humans on high-dose B6 supplementation. The mechanism may involve direct neurotoxicity of unbound pyridoxine or saturation of pyridoxal kinase with downstream metabolic disturbance. The clinical context is essentially never seen with commercial pet food but warrants caution in over-the-counter B6 supplementation outside veterinary direction. The safety margin is wide at AAFCO-compliant dietary concentrations.
What to do if you bought affected product
Pet owners can manage vitamin B6 adequacy through several practical approaches: (1) most healthy pets on AAFCO-compliant commercial diets receive adequate vitamin B6 through the combination of supplemented pyridoxine HCl premix and natural pyridoxal / pyridoxamine from animal-tissue ingredients; named-meat-anchored and organ-meat-inclusive formulations deliver substantial natural B6 contribution beyond the supplemented dose; (2) for plant-protein-heavy formulations, request brand customer-service confirmation that B6 supplementation accounts for PNG plant-glycoside non-bioavailability in legume and grain-bran fractions; the riboflavin adequacy framework (covered in our riboflavin stability controversy page) is structurally linked because riboflavin-dependent oxidase activates PNP to PLP; (3) pets on isoniazid or prolonged sulfonamide therapy may benefit from veterinary-guided B6 supplementation under prescribing-veterinarian coordination; (4) do not stack high-dose B6 supplementation on AAFCO-compliant commercial diet without veterinary indication — chronic pharmacologic-dose pyridoxine can produce sensory neuropathy through the same mechanism documented in human supplementation literature; (5) request B6 source form from brand customer service for boutique or specialty formulations — standard pyridoxine HCl is the dominant pet food premix form; direct PLP supplementation is essentially absent from the commercial dry-kibble category but appears in some veterinary therapeutic diets; (6) watch for microcytic hypochromic anemia signs — lethargy, pale gums, exercise intolerance with low MCV on complete blood count warrant veterinary investigation including B6 status assessment.
How this affects KibbleIQ’s grade
The KibbleIQ rubric v15 does not currently differentiate vitamin B6 source form per our published methodology, since brand-level disclosure of pyridoxine HCl versus natural PL / PLP contribution is essentially absent. The PNG plant-glycoside bioavailability gap and the riboflavin-dependent oxidase activation framework are structural considerations that warrant brand-level transparency over time. Future rubric extension under consideration: brands publishing natural B6 quantification from named-meat and organ-meat ingredients (especially liver and tuna inclusion) would receive favorable scoring weight reflecting more direct functional B6 delivery; brands using direct PLP supplementation or addressing the PNG bioavailability gap with formulation-specific calibration would receive scoring credit. For now, our recommendation: assume AAFCO-compliant commercial diets meet B6 requirements adequately for healthy pets; treat plant-protein-heavy formulations as warranting brand inquiry about supplementation margin; and treat high-dose over-the-counter B6 supplementation as a veterinary-supervised intervention rather than a routine dietary addition.